Radotinib

Radotinib, and sometimes referred to by its investigational name IY5511, is a drug for the treatment of different types of Y, most notably Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) with resistance or intolerance of other tyrosine kinase Bcr-Abl inhibitors

Price Not Available 50 mg Radotinib Supplier Page
Catalog Number T2328
Alternative Name(s) IY-5511 , Supect
Research Area Cytoskeletal Signaling|||Tyrosine Kinase/Adaptors|||Angiogenesis
Molecular Formula C27H21F3N8O
CAS# 926037-48-1
Purity 99.70%
SMILES Cc1c(cc(cc1)C(=O)Nc1cc(cc(c1)n1cc(nc1)C)C(F)(F)F)Nc1nccc(n1)c1nccnc1
Size 50 mg
Supplier Page https://www.targetmol.com/compound/Radotinib
Additional Information https://www.targetmol.com/datasheet/T2328